Medannex is an award-winning clinical-stage Scottish biopharmaceutical company unlocking the therapeutic potential of targeting annexin-A1.
“Annexin-A1 may prove a very significant clinical target, and blocking its activity with MDX-124 could represent a completely new and exciting way to treat cancer. We are delighted to be leading the first-in-human study.”
Professor Daniel Palmer,
Liverpool Clinical Trial Centre
We are pioneering the targeting of annexin-A1 to provide powerful new treatment options for people impacted by cancers and autoimmune diseases.
Annexin-A1 drives tumour growth and metastasis and also plays a key role in the development of several autoimmune conditions. Extensive pre-clinical data demonstrate that our first-in-class monoclonal antibody (MDX-124) effectively blocks the negative action of annexin-A1.
A Phase 1b clinical study is underway, showing disease control, tumour shrinkage and negligible toxicity in cancer patients across multiple tumour types. In parallel, we are currently preparing for further clinical studies in autoimmune diseases and developing antibody-drug conjugates (ADCs) based on MDX-124.
Medannex is collaborating with world-leading clinical experts to explore the huge therapeutic and commercial potential of our patent-protected technology.
